DRDATSONS

Finaventure Capital Limited has submitted to the Exchange vide its letter dated May 11, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated May 09, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Kannan Vishwanath has informed the Exchange vide letter dated May 9, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated April 30, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated April 26, 2012, a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4), 13(4A) and (6) of SEBI (Prohibition of Insider Trading) Regulations,1992.

Aanjaneya Lifecare Limited has informed the Exchange that the Company has opted for submitting audited financial results for the year ended March 31, 2012 within 60 days from the end of financial year. In view of the above, Company would not be submitting Un-audited financial results for the quarter ending March 31, 2012.

Aanjaneya Lifecare Limited has informed the Exchange regarding a press release dated April 19, 2012 titled "Aanjaneya Wins 'Best Practices in Corporate Governance Award' ".

Aanjaneya Lifecare Limited has informed the Exchange that the company won the "Europe Awards Best Practices in Corporate Governance 2012" by European Society of Quality Research at Amsterdam Holland on April 15, 2012.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated April 13, 2012, a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4), 13(4A) and (6) of SEBI (Prohibition of Insider Trading) Regulations,1992 for acquisition of 50,000 shares.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 13, 2012 : (1) Approved and accepted the retirement of Mr. Kashi Vishwanathan, Chairman and Whole time Director of the Company as per the terms of reference of the code of conduct drafted for the Management & Board of Directors of the Company.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated April 11, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4), 13(4A) and (6) of SEBI (Prohibition of Insider Trading ) Regulations ,1992 for acquisition of 50,000 shares.

Aanjaneya Lifecare Limited has informed the Exchange regarding a press release dated April 09, 2012, titled "Aanjaneya Lifecare debuts new fiscal with 3 global recognitions".

Aanjaneya Lifecare Limited has informed the Exchange that the company received the following awards on April 06, 2012 : (1) The IMC Ramkrishna Bajaj National Quality Awards 2012 "Certificate of Merit" in Small Business Catagory at NCAP in Mumbai; (2) Company awarded the "Best Corporate Governance, India, 2012" at the 3rd Annual India Business Ship Conclave & India Business Awards 2012; (3) Dr. Kannan Vishwanath Received the "Business Leader of Year 2012" at the 3rd Annual India Business Ship Conclave & India Business Awards 2012.

Kannan Vishwanath has submitted to the Exchange vide its letter dated March 30, 2012 a revised copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Kannan Vishwanath has submitted to the Exchange vide its letter dated April 02, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 30, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has informed the Exchange that in the Meeting of the Board of Directors of the Company held on April 02, 2012, the Board of Directors decided : (1) To issue securities/Foreign Currency Convertible Bonds to the tune of 75 million USD to Qualified Institutional Buyers (QIBs) [to be identified by the Investment Committee of the Company] through Qualified Institutional Placement (QIP) in tranches over a period of 18 months out of which first tranche would aggregate to 25 million USD to be allocated for ongoing capital expenditure & potential acquisitions; (2) To appoint

Apex Drugs & Intermediates Limited has submitted to the Exchange vide its letter dated March 28, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading ) Regulations ,1992 for purchase of 1310484 shares of the company.

Aanjaneya Lifecare Limited has informed the Exchange that Meeting of the Board of Directors of the company held on March 28, 2012, the Board has (1) Approved and allotted 13,10,484 Equity Shares of Rs 10/- each on preferential basis at price of Rs. 496/- per equity share for consideration other than cash to M/s Apex Drugs and Intermediates Limited (being Non Promoter) on Preferential allotment basis in accordance with the resolution passed by the members at the Extra General Meeting held on February 27, 2012.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 27, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 24, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4) and (6) of SEBI (Prohibition of Insider Trading ) Regulations ,1992.

Kannan Vishwanath has submitted to the Exchange vide its letter dated March 27, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 22, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 21, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4) and (6) of SEBI (Prohibition of Insider Trading ) Regulations ,1992.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 21, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure under Regulation 13(4) and (6) of SEBI (Prohibition of Insider Trading ) Regulations ,1992.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 19, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Religare Finvest Limited has submitted to the Exchange a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 16, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Religare Securities Limited has submitted to the Exchange, vide letter dated March 14, 2012 a copy of Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 15, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Religare Securities Limited has submitted to the Exchange a copy of Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 with respect to sale of 800,000 shares of Aanjaneya Lifecare Limited.

Religare Securities Limited has submitted to the Exchange vide its letter dated March 14, 2012 a copy of Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 with respect to acquisition of 800,112 shares of Aanjaneya Lifecare Limited.

Aanjaneya Lifecare Limited has informed the Exchange that Aanjaneya Lifecare Limited [ALL] became holding Company of EROS PHARMACHEM PTE. LIMITED, a Company incorporated in the Republic of Singapore, by way of acquiring 90% ordinary share capital of the said Singapore based Company.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 09, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has submitted to the Exchange a copy of the Minutes of the Extra Ordinary General Meeting of the Company held on February 27, 2012.

Finaventure Capital Limited has submitted to the Exchange vide its letter dated March 2, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 with respect to acquisition of 20,000 shares of Aanjaneya Lifecare Limited.

Aanjaneya Lifecare Limited has informed the Exchange that as decided in the Extra Ordinary General Meeting of the Company held on February 27, 2012 the Members of the Company has approved and passed the following Special Resolution for: (1) Issuance of 1310484 equity shares on preferential basis at price of Rs.496/- per equity share (being the price determined under SEBI (ICDR) Regulations, 2009), to Apex Drugs & Intermediates Limited.

Finaventure Capital Limited has submitted to the Exchange a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended December 31, 2011 (taken on record by the Board of Directors of the Company at its meeting held on January 30, 2012) regarding the Utilisation of funds.

Aanjaneya Lifecare Limited has informed the Exchange regarding the Outcome of the Meeting of the Board of Directors of the Company held on February 02, 2012.

Aanjaneya Lifecare Limited has informed the Exchange regarding a press release dated February 02, 2012 titled "Aanjaneya Lifecare acquires Apex Drug and Intermediates".

Aanjaneya Lifecare Limited has informed the Exchange regarding a press release dated January 30, 2012, titled "Aanjaneya Lifecare Ltd; Q3 FY12".

Aanjaneya Lifecare Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31,2011.

Kannan Vishwanath has submitted to the Exchange vide its letter dated January 10, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for sale of 47000 shares.

Kannan Vishwanath has submitted to the Exchange a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 9, 2012 has: (1) Decided to authorize Dr. Kannan Vishwanath, Managing Director of the Company, to negotiate the terms and conditions for acquisition of 100% Assets and business of Apex Drugs & Intermediates Limited; (2) Decided to open subsidiary companies and offices in Singapore and U.A.E and authorize Dr. Kannan Vishwanath, Managing Director or any of the Director of the Company.

Finaventure Capital Limited has submitted to the Exchange a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has informed the Exchange regarding a press release dated December 21, 2011, titled "Aanjaneya Lifecare Ltd wins two Prestigious Recognitions at 4th Annual Pharma Leadership Summit & Awards 2011".

Kannan Vishwanath has submitted to the Exchange a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 and disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.